Epsilon Healthcare Ltd (ASX: EPN) 宣布,其子公司Epsilon Pharma在为期三年的初始合作期内,预计制造业务收入将达到600万澳元。这一预测凸显了公司在医药制造领域的增长潜力和业务稳定性。
Epsilon Healthcare Ltd (ASX: EPN) 宣布,其子公司Epsilon Pharma在为期三年的初始合作期内,预计制造业务收入将达到600万澳元。这一预测凸显了公司在医药制造领域的增长潜力和业务稳定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.